

Earnings Highlights

\$27.7B

+53% Op Growth<sup>1</sup>

\$1.73 Rep. Dil. EPS

+77% Growth \$2.04 Adj. Dil. EPS<sup>2</sup> +100%

Op Growth

\$2.8B Rep. R&D Expenses

+27% Op Growth

\$2.8B Adj. R&D Expenses<sup>2</sup>

+27% Op Growth

Revenue \$98B-\$102B Adj. Dil. EPS<sup>2</sup> \$6.30-\$6.45

FY 2022 Guidance<sup>3</sup>

**Returned to Shareholders** Year-To-Date \$4.5B Cash Dividends \$2.0B Share Repurchases

shareholders, while also making commitments to prioritize the broader needs of the world, including those of the environment and our most vulnerable populations. Even while launching these initiatives to support a healthier, more equitable world, we remain equally committed to strong financial execution on behalf of our shareholders." **Albert Bourla** 

"We made significant progress this quarter on our strategies to bring value to our patients and

Chairman and Chief Executive Officer



## **PAXLOVID**<sup>™</sup> \$8,848M Revenue

Key Growth Drivers

Pfizer-BioNTech

\$1,745M Revenue

+23% Op Growth

+20% Op Growth

Prevnar

**Family** 

Pneumococcal Conjugate Vaccine

COVID-19 Oral Treatment

\$8,115M Revenue

Eliquis.

(apixaban) tablets

Vyndamax

\$552M Revenue<sup>o</sup> +16% Op Growth +32% U.S. Growth

\$1,429M Revenue<sup>5</sup>

+18% Op Growth

+41% U.S. Growth



Pipeline Spotlights

## Pfizer-BioNTech Omicron-Adapte

Etrasimod

Candidate

Pfizer-BioNTech

Candidate Ervogastat/ Clesacostat

**Combination Therapy** 

Candidate

Candidate Elranatamab

Completed Acquisition

**Proposed Acquisition** bĭohaven

Vaccines Internal Medicine Inflammation/Immunology

Oncology Rare Disease



## Up to Potential Proof of Concept Readouts

What's Next

Reaffirm projected revenue CAGR of at least 6% and double-digit adjusted diluted EPS<sup>2</sup> growth through 2025<sup>8</sup>


Projected Pivotal Readouts

Maintain platforms



Invest in areas we can win





investors.pfizer.com

Ambition of up to 25 breakthrough launches in patients' hands by 2025

reported EPS attributable to Pfizer Inc. common shareholders—diluted before the impact of amortization of intangible assets, certain acquisition-related items, discontinued operations and certain significant items. Adjusted research and development (R&D) expenses

earnings release furnished with Pfizer's Current Report on Form 8-K dated July 28, 2022 for additional information.

<sup>5</sup> Prevnar family include revenues from Prevnar 13/Prevenar 13 (pediatric and adult) and Prevnar 20/Apexxnar (adult).

Please reference Pfizer's Q2 2022 earnings release and SEC filings for additional information.

See the reconciliations of certain GAAP Reported to Non-GAAP Adjusted information for the second quarter and first six months of 2022 and 2021 of Pfizer's earnings release furnished with Pfizer's Current Report on Form 8-K dated July 28, 2022. The Adjusted income and its components and Adjusted diluted EPS measures are not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS, have no standardized meaning prescribed by U.S. GAAP and may not be comparable to the calculation of similar measures of other companies. See the Non-GAAP Financial Measure: Adjusted Income section of Management's Discussion and Analysis of Financial Condition and Results of Operations in Pfizer's 2021 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the quarterly period ended April 3, 2022 and the Non-GAAP Financial Measure: Adjusted Income section of Pfizer's

<sup>1</sup> Operational growth. Reference to operational variances pertain to period-over-period changes that exclude the impact of foreign

Projected revenue CAGR calculated from 2020–2025. Excludes the impact of Pfizer-BioNTech COVID-19 vaccine (Comirnaty) and the COVID-19 oral treatment (Paxlovid), as well as recent or subsequent business development activities. supply and dividends that are subject to substantial risks and uncertainties that could cause actual results to differ materially from 2021, and Pfizer's subsequent reports on Form 10-Q, including the sections thereof captioned "Risk Factors" and "Forward-Looking Information and Factors That May Affect Future Results," as well as Pfizer's subsequent reports on Form 8-K for a description of the substantial risks and uncertainties related to the forward-looking statements included in this document. These reports are available on Pfizer's website at www.pfizer.com and on the U.S. Securities and Exchange Commission's website at www. sec.gov. The forward-looking statements in this document speak only as of the original date of this document, and we undertake no obligation to update or revise

<sup>7</sup> Reference the full set of materials in the Q2 2022 Earnings Presentation for certain information regarding potential approvals and

<sup>3</sup> Total company guidance. <sup>4</sup> Q2 financial performance.